News | Heart Valve Technology | June 08, 2020

Edwards Sapien 3 Transcatheter Heart Valve Receives Approval In China


June 8, 2020 — Edwards Lifesciences Corp. announced Chinese regulatory approval for the Edwards Sapien 3 transcatheter aortic valve replacement (TAVR) system for the treatment of patients suffering from severe, symptomatic aortic stenosis (AS) at high risk for or unable to undergo open-heart surgery.

"Now, in China, patients diagnosed with severe AS have the option of a shorter procedure with excellent clinical outcomes, including a more rapid recovery than open-heart surgery," said Prof. Junbo Ge, M.D., academician of the Chinese Academy of Sciences, chairman, Shanghai Institute of Cardiovascular Diseases and director, Department of Cardiology, Zhongshan Hospital, Fudan University.

The Sapien 3 valve builds on Edwards' decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards Sapien transcatheter heart valves. The Sapien TAVR valves are the most widely studied transcatheter valves, with more than 30,000 patients treated in clinical trials and registries in over 65 countries around the world. The approval for high-risk and extreme-risk patients in China was supported by the China Sapien 3 study, which complements a highly robust set of clinical outcomes from three randomized controlled PARTNER studies, along with excellent real-world results.

"This approval marks a major milestone for Chinese physicians and their patients living with severe AS in need of alternatives to open-heart surgery," said Larry L. Wood, Edwards' corporate vice president, TAVR. "Edwards is proud to introduce this technology, which has demonstrated successful outcomes for patients worldwide, into China. We look forward to partnering with hospitals throughout China to introduce this therapy through our comprehensive, globally proven training program."  

The valve, available in 20, 23, 26 and 29 mm sizes, is approved by the National Medical Products Administration for treating high-risk patients in China. To date, more than 650,000 patients around the world have benefitted from TAVR.

For more information: www.Edwards.com

 

Related Sapien 3 TAVR Content:

TAVR Equivalent to Surgery at Two Years in Low-Risk Patients

Key TAVR Takeaways From ACC 2020

VIDEO: TAVR Performs as Well as Surgery in Low-Risk Patients — Interview with Michael Mack, M.D.

TAVR Equivalent to Surgery at Two Years in Low-Risk Patients

Sapien 3 Valve Shows Favorable One-Year Results in PARTNER II Trial

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now